BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 34012060)

  • 1. The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients.
    Bauckneht M; Bertagna F; Donegani MI; Durmo R; Miceli A; De Biasi V; Laudicella R; Fornarini G; Berruti A; Baldari S; Versari A; Giubbini R; Sambuceti G; Morbelli S; Albano D
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1198-1207. PubMed ID: 34012060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with
    Wibmer AG; Morris MJ; Gonen M; Zheng J; Hricak H; Larson S; Scher HI; Vargas HA
    J Nucl Med; 2021 Aug; 62(8):1050-1056. PubMed ID: 33419944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223.
    Bauckneht M; Capitanio S; Donegani MI; Zanardi E; Miceli A; Murialdo R; Raffa S; Tomasello L; Vitti M; Cavo A; Catalano F; Mencoboni M; Ceppi M; Marini C; Fornarini G; Boccardo F; Sambuceti G; Morbelli S
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861942
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Caroli P; De Giorgi U; Scarpi E; Fantini L; Moretti A; Galassi R; Celli M; Conteduca V; Rossi L; Bianchi E; Paganelli G; Matteucci F
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):348-354. PubMed ID: 29110067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of volumetric parameters obtained from
    Güzel Y; Kömek H; Can C; Kaplan İ; Akdeniz N; Kepenek F; Gündoğan C
    Ann Nucl Med; 2023 Sep; 37(9):517-527. PubMed ID: 37332068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy, prognostic variables and clinical outcome of
    Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
    Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
    BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [
    Buteau JP; Martin AJ; Emmett L; Iravani A; Sandhu S; Joshua AM; Francis RJ; Zhang AY; Scott AM; Lee ST; Azad AA; McJannett MM; Stockler MR; Williams SG; Davis ID; Hofman MS;
    Lancet Oncol; 2022 Nov; 23(11):1389-1397. PubMed ID: 36261050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer.
    Fox JJ; Gavane SC; Blanc-Autran E; Nehmeh S; Gönen M; Beattie B; Vargas HA; Schöder H; Humm JL; Fine SW; Lewis JS; Solomon SB; Osborne JR; Veach D; Sawyers CL; Weber WA; Scher HI; Morris MJ; Larson SM
    JAMA Oncol; 2018 Feb; 4(2):217-224. PubMed ID: 29121144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prognostic Value of Posttreatment
    Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L
    J Nucl Med; 2023 Jan; 64(1):69-74. PubMed ID: 35738906
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline
    Garcia-Vicente AM; Pérez-Beteta J; Amo-Salas M; Molina D; Jimenez-Londoño GA; Soriano-Castrejón AM; Pena Pardo FJ; Martínez-González A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):73-79. PubMed ID: 29102649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223.
    Bauckneht M; Lai R; D'Amico F; Miceli A; Donegani MI; Campi C; Schenone D; Raffa S; Chiola S; Lanfranchi F; Rebuzzi SE; Zanardi E; Cremante M; Marini C; Fornarini G; Morbelli S; Piana M; Sambuceti G
    Ann Nucl Med; 2022 Apr; 36(4):373-383. PubMed ID: 35044592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
    Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
    Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria.
    Velez EM; Desai B; Ji L; Quinn DI; Colletti PM; Jadvar H
    Theranostics; 2020; 10(7):3254-3262. PubMed ID: 32194866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer.
    Hu WD; Wang HC; Wang YB; Cui LL; Chen XH
    Q J Nucl Med Mol Imaging; 2021 Jun; 65(2):172-177. PubMed ID: 30916535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis.
    Alamiri J; Britton CJ; Ahmed ME; Andrews JR; Higa JL; Dundar A; Karnes RJ; Kwon E; Lowe VJ; Kendi AT; Bold MS; Pagliaro LC
    Prostate; 2022 Dec; 82(16):1483-1490. PubMed ID: 36089822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.